Skip to main content
59°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Equillium, Inc.
< Previous
1
2
Next >
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
August 06, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
July 18, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Participate in Upcoming Investor Conferences
July 02, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to be included in the Russell Microcap® Index
June 12, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
May 14, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
May 07, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
April 01, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
March 25, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
March 22, 2024
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
December 21, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
November 13, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
November 08, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
November 06, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Host Analyst & Investor Day
October 03, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the JonesTrading 2023 Healthcare Summit
October 02, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences
September 20, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference
August 30, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
August 09, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces $7.5 Million Share Repurchase Program
August 02, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences
June 01, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
May 15, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
May 11, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation
April 24, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates
March 23, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference
March 22, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR
February 17, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the SVB Securities Annual Global Healthcare Conference
February 07, 2023
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.